FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,700 | +127.5% | 47,500 | +410.8% | 0.01% | +133.3% |
| Q2 2023 | $44,268 | +3783.2% | 9,300 | +4550.0% | 0.00% | – |
| Q1 2023 | $1,140 | -99.6% | 200 | -99.3% | 0.00% | -100.0% |
| Q4 2022 | $273,439 | +296.3% | 27,100 | +774.2% | 0.02% | +300.0% |
| Q3 2022 | $69,000 | -89.2% | 3,100 | -71.3% | 0.01% | -89.4% |
| Q3 2021 | $641,000 | +2110.3% | 10,818 | +3119.6% | 0.05% | +2250.0% |
| Q2 2021 | $29,000 | +93.3% | 336 | +75.0% | 0.00% | +100.0% |
| Q1 2021 | $15,000 | 0.0% | 192 | +12.3% | 0.00% | -50.0% |
| Q4 2020 | $15,000 | -57.1% | 171 | -80.7% | 0.00% | -50.0% |
| Q3 2020 | $35,000 | -51.4% | 885 | -76.1% | 0.00% | -42.9% |
| Q4 2019 | $72,000 | +1700.0% | 3,700 | +1133.3% | 0.01% | – |
| Q3 2019 | $4,000 | – | 300 | +305.4% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 74 | -99.3% | 0.00% | -100.0% |
| Q1 2018 | $107,000 | – | 10,984 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |